Evidence map›Paper›PMID 24719318›Full record

ArticleThe Journal of biological chemistry2014

Pancreatic cancer stem-like cells display aggressive behavior mediated via activation of FoxQ1.

Bin Bao, Asfar S Azmi, Amro Aboukameel, Aamir Ahmad, Aliccia Bolling-Fischer, Seema Sethi, Shadan Ali, Yiwei Li, Dejuan Kong, Sanjeev Banerjee and 2 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The transcription factor FOXQ1 in cancer.Cancer metastasis reviews · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2021
    Review
  18. Enrichment of Melanoma Stem-Like Cells via Sphere Assays.Methods in molecular biology (Clifton, N.J.) · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Bin BaoFrom the Department of Pathology.
Asfar S AzmiFrom the Department of Pathology.
Amro AboukameelGenomics Core Facility.
Aamir AhmadFrom the Department of Pathology.
Aliccia Bolling-FischerGenomics Core Facility.
Seema SethiFrom the Department of Pathology.
Shadan AliDepartment of Oncology, and.
Yiwei LiFrom the Department of Pathology.
Dejuan KongFrom the Department of Pathology.
Sanjeev BanerjeeFrom the Department of Pathology.
Jessica BackFlow Cytometry Core Facility, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201.
Fazlul H SarkarFrom the Department of Pathology, Genomics Core Facility, fsarkar@med.wayne.edu.
Wayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Subpopulations of cancer stem cells (CSCs) or cancer stem-like cells (CSLCs) have been identified from most tumors, including pancreatic cancer (PC), and the existence of these cells is clinically relevant. Emerging evidence suggests that CSLCs participate in cell growth/proliferation, migration/invasion, metastasis, and chemo-radiotherapy resistance, ultimately contributing to poor clinical outcome. However, the pathogenesis and biological significance of CSLCs in PC has not been well characterized. In the present study, we found that isolated triple-marker-positive (CD44(+)/CD133(+)/EpCAM(+)) cells of human PC MiaPaCa-2 and L3.6pl cells behave as CSLCs. These CSLCs exhibit aggressive behavior, such as increased cell growth, migration, clonogenicity, and self-renewal capacity. The mRNA expression profiling analysis showed that CSLCs (CD44(+)/CD133(+)/EpCAM(+)) exhibit differential expression of more than 1,600 mRNAs, including FoxQ1, compared with the triple-marker-negative (CD44(-)/CD133(-)/EpCAM(-)) cells. The knockdown of FoxQ1 by its siRNA in CSLCs resulted in the inhibition of aggressive behavior, consistent with the inhibition of EpCAM and Snail expression. Mouse xenograft tumor studies showed that CSLCs have a 100-fold higher potential for tumor formation and rapid tumor growth, consistent with overexpression of CSC-associated markers/mediators, including FoxQ1, compared with its parental MiaPaCa-2 cells. The inhibition of FoxQ1 attenuated tumor formation and growth, and expression of CSC markers in the xenograft tumor derived from CSLCs of MiaPaCa-2 cells. These data clearly suggest the role of differentially expressed genes in the regulation of CSLC characteristics, further suggesting that targeting some of these genes could be important for the development of novel therapies for achieving better treatment outcome of PC.

Indexed as

AC133 AntigenAnimalsAntigens, CDAntigens, NeoplasmApoptosisBlotting, WesternCell Adhesion MoleculesCell CycleCell Line, TumorCell MovementCell ProliferationEpithelial Cell Adhesion MoleculeForkhead Transcription FactorsGene Expression ProfilingGene Expression Regulation, NeoplasticGlycoproteinsAC133 AntigenAntigens, CDAntigens, NeoplasmCell Adhesion MoleculesEPCAM protein, humanEpithelial Cell Adhesion MoleculeForkhead Transcription FactorsFOXQ1 protein, humanGlycoproteinsHyaluronan ReceptorsPeptidesPROM1 protein, humanProm1 protein, mouseCancer Stem CellsCD44Flow CytometryGene ExpressionMicroarrayPancreatic CancersiRNATumor Growth

Identifiers

PMID24719318
PMCPMC4031510
OpenAlexW2077957701

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.